Indian Journal of Research in Homeopathy

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 11  |  Issue : 2  |  Page : 97--108

Homoeopathic pathogenetic trial of Withania somnifera: A multicentric, double-blind, randomised, placebo-controlled trial


Pritha Mehra1, Anil Khurana2, Renu Mittal2, Bhopal Singh Arya1, Rajpal3, Raj K Manchanda2, Karuna Singh1, Anil K Vichitra1, Goutam Rakshit2, Jai P Singh4, Maya Padmanabhan2 
1 Dr. D. P. Rastogi Central Research Institute (H), Noida, Uttar Pradesh, India
2 Central Council for Research in Homoeopathy, New Delhi, India
3 Homoeopathic Treatment Center, Safdurjung Hospital, New Delhi, India
4 Homoeopathic Drug Research Institute, Lucknow, Uttar Pradesh, India

Correspondence Address:
Pritha Mehra
Dr. D. P. Rastogi Central Research Institute (H), A 1/1, Sector 24, Noida, Uttar Pradesh
India

Background: Homoeopathic drug proving being the first step in finding the pathogenetic powers of a drug is an integral part of Homoeopathic system of medicine. Objective: To elicit the pathogenetic response of Withania somnifera in homoeopathic potencies on healthy human provers. Materials and Methods: A multicentre, randomised, double-blind, placebo-controlled trial was conducted at four centres under Central Council for Research in Homoeopathy. Proving was conducted on 63 relatively healthy provers. All the provers were given 12 doses of placebo divided into 4 doses/day for 3 days during the first phase of the trial. After randomisation, 43 provers in the intervention group were given W. somnifera in 6C and 30C potencies in two phases. In the placebo group, 20 provers were administered unmedicated globules. The symptoms and signs manifested during the trial were noted down by the provers, elaborated by the proving masters and the data compilation on W. somnifera was done at proving-cum-data processing cell. Results: Out of 43 provers who were on actual drug trial, only 15 provers manifested 39 symptoms. The symptoms have been manifested predominantly in 30C potency. Among the objective findings, the drug has shown its effect on kidney, ovaries and helminthic infestation. Conclusion: The pathogenetic response elicited during this trial expands the scope of the use of W. somnifera and needs to be further validated by clinical verification study.


How to cite this article:
Mehra P, Khurana A, Mittal R, Arya BS, Rajpal, Manchanda RK, Singh K, Vichitra AK, Rakshit G, Singh JP, Padmanabhan M. Homoeopathic pathogenetic trial of Withania somnifera: A multicentric, double-blind, randomised, placebo-controlled trial.Indian J Res Homoeopathy 2017;11:97-108


How to cite this URL:
Mehra P, Khurana A, Mittal R, Arya BS, Rajpal, Manchanda RK, Singh K, Vichitra AK, Rakshit G, Singh JP, Padmanabhan M. Homoeopathic pathogenetic trial of Withania somnifera: A multicentric, double-blind, randomised, placebo-controlled trial. Indian J Res Homoeopathy [serial online] 2017 [cited 2021 Mar 4 ];11:97-108
Available from: https://www.ijrh.org/article.asp?issn=0974-7168;year=2017;volume=11;issue=2;spage=97;epage=108;aulast=Mehra;type=0